Details:
The pioneering Phase II clinical trial is the first human research investigating the potential of a microdose of psilocybin to improve behavioural and cognitive symptoms associated with Fragile X syndrome.
Lead Product(s): Psilocybine
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Nova Mentis Life Science
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 17, 2022
Details:
Nova Mentis has filed a genetic neuroinflammatory disease patent which describes a diagnostic/therapeutic combination of mRNA molecules that encode proteins involved in the development of neurogenerative diseases, including fragile X syndrome and autism spectrum disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
With no treatments currently available, Oak Bay Biosciences ‘Lead Molecule’ could be more than 90% effective in preventing the retinal cell death associated with Stargardt disease.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: FrontFundr
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 29, 2021
Details:
Proceeds will be used to develop Inversago’s best-in-class peripherally-acting CB1 inverse agonist candidate INV-101 to clinical proof-of-concept, and advance the research on other selected compounds.
Lead Product(s): INV-101
Therapeutic Area: Genetic Disease Product Name: INV-101
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Forbion
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 08, 2020
Details:
IRICoR's investment enabled ExCellThera to secure the co-funding required in connection with the grant awarded to it from the California Institute for Regenerative Medicine for a Phase 1 clinical trial using its ECT-001, for the treatment of severe sickle cell disease.
Lead Product(s): ECT-001
Therapeutic Area: Genetic Disease Product Name: ECT-001
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: IRICoR
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 07, 2020